公开(公告)号：US20070218000A1

公开(公告)日：2007-09-20

申请号：US10580508

申请日：2004-12-02

申请人： Rolando Feyt ,  Enrique Gerardo ,  Gretel Sardinas Garcia ,  Nunez Lazaro Betancourt ,  Serra Castellanos ,  Negrin Perera ,  Diaz Garcia ,  Perez Niebla ,  Menendez Caballero ,  Blanco Gonzalez

发明人： Rolando Feyt ,  Enrique Gerardo ,  Gretel Sardinas Garcia ,  Nunez Lazaro Betancourt ,  Serra Castellanos ,  Negrin Perera ,  Diaz Garcia ,  Perez Niebla ,  Menendez Caballero ,  Blanco Gonzalez

IPC分类号： A61K39/02 ,  A61K39/00 ,  A61K49/00 ,  C07K14/00 ,  C12N1/00 ,  C12Q1/68 ,  G01N33/53

CPC分类号： C07K14/22 ,  A61K39/00 ,  A61K2039/523 ,  A61K2039/53

摘要： Use of a novel vaccine antigen applied in a preventive or therapeutic way against diseases in general, being such disease of bacterial, viral, cancer related, or other origin. The technical objective that this invention pursues is the development of formulations with the ability to increase the protective spectrum of existing vaccines and hence expanding it against different pathogens. In order to achieve this goal the NMB1125 protein was isolated and identified as a component of outer membrane preparations of Neisseria meningitidis capable of inducing bactericidal activity. Additionally, the gene codifying for NMB1125 protein was cloned and expressed, and the said polypeptide was purified and its immunogenicity evaluated in animal models. The sequence data from homologous genes showed, due to the high degree of conservation, its high value as a target antigen of a cross-reactive response when it is presented by different routes. Resultant formulations of this invention are of use in the pharmaceutical industry as vaccine formulations for human use.

摘要翻译： 使用以预防或治疗方式应用的新型疫苗抗原，通常可以防止一般疾病，这些细菌，病毒，癌症相关或其它来源的疾病。 本发明所追求的技术目标是开发具有增加现有疫苗的保护性能并因此扩增其抵抗不同病原体的能力的制剂。 为了达到这个目标，NMB1125蛋白被分离并鉴定为能够诱导杀菌活性的脑膜炎奈瑟氏球菌外膜制剂的组分。 另外，克隆和表达编码NMB1125蛋白的基因，并且将所述多肽纯化，并在动物模型中评估其免疫原性。 来自同源基因的序列数据显示，由于高度的保守性，当通过不同途径呈现时，其作为交叉反应性应答的靶抗原的高值显示出来。 本发明的所得制剂在制药工业中用作人类使用的疫苗制剂。